key: cord-0257988-ncckjqaq
authors: Tamuzi, J. J.; Lulendo, G.; Mbuesse, P.
title: The incidence and mortality of COVID-19 related TB infection in Sub-Saharan Africa: A systematic review and meta-analysis
date: 2022-01-11
journal: nan
DOI: 10.1101/2022.01.11.22269065
sha: d901f3b5df2064eb74a089f5a26ea47072affb51
doc_id: 257988
cord_uid: ncckjqaq

Background Coronavirus disease 2019 (COVID-19) is also associated with other co-morbidities among with previous and current pulmonary tuberculosis (PTB). PTB is a risk factor for COVID-19, both in terms of severity and mortality, regardless of human immunodeficiency virus (HIV) status. However, there is less information available on COVID-19 associated with PTB in point of view incidence and mortality rates in sub-Saharan Africa (SSA) as a high burden TB region. This systematic review served to provide data synthesis of available evidence on COVID-19/PTB incidence and case fatality rates, and mortality rate found in clinical and post-mortem COVID-19/PTB diagnostics in SSA. Methods We conducted a systematic electronic search in the PubMed, Medline, Google Scholar, Medrxix and COVID-19 Global literature on coronavirus disease databases for studies including COVID-19 associated with PTB in sub-Saharan Africa. The main outcomes were the proportion of people with COVID-19 associated to current /or previous PTB and the case fatality associated to COVID-19/PTB. The combination method was based on methodological similarities in the included random effect model studies using Prometa 3 software. We further undertook sensitivity analysis and meta-regression. Results From the 548 references extracted by the literature search, 25 studies were selected and included in the meta-analysis with a total of 191, 250 COVID-19 infected patients and 11, 452 COVID-19 deaths. The pooled COVID-19/PTB incidence was 2% [1%-3%] and mortality of 10% [4%-20%]. The pooled estimates for case fatality rate among COVID-19/PTB were 6% [3%-11%] for clinical PTB diagnostic and 26% [14%-48%] for post-mortem PTB diagnostic. Meta-regression model including the effect sizes and cumulative COVID-19 cases (P= 0.032), HIV prevalence (P= 0.041) and TB incidence (P= 0.002) to explained high heterogeneity between studies. Conclusion As a summary, the incidence of TB associated with COVID-19 and case fatality rates are higher in SSA. However, COVID-19 associated to TB may be underreported in the studies conducted in SSA as the post-mortem TB diagnostic was higher. Large-scale cohort studies that adequately clear tool on previous and/or current TB diagnostic tools are required to confirmed COVID-19/TB incidence and case fatality in SSA.

 4 

The coronavirus disease 2019 (COVID-19) pandemic has caused significant morbidity and mortality all over the world, with total confirmed cases of 296,496,809 globally and 5,462,631 deaths in January 2022 [1] . In African region, 7,493,439 confirmed cases are already recorded, among them, 154, 837 deaths in January 2022 [1] . Though it is reported that the African region showed a decreasing trend in the number deaths over the past several weeks compared to other WHO regions [1] . The age groups at highest risk of severe COVID-19 disease and death (those >60 years old) [2] [3] [4] may be proportionately less in many SSA countries than in other parts of the world [4] . In contradistinction to potential health vulnerabilities, sub-Saharan African countries could be "protected" from COVID-19 mortality by an age structure differing significantly from countries where morbidity and mortality has been particularly high such as Italy, Spain, the United States, and in Hubei Province in China [5-7].

However, COVID-19 is also associated with other co-morbidities among with previous and current pulmonary tuberculosis (PTB) [8] . A recent review has shown that TB is a risk factor for COVID-19, both in terms of severity and mortality, regardless of HIV status [8] .

Geographically, most people who developed TB are in South-East Asia (44%), Africa (25%) and the Western Pacific (18%) [9] . It is estimated that 94% of all TB infections and deaths occur appropriately in low-and middle-income countries, including sub-Saharan Africa (SSA) [10] . An observational study suggested that individuals with latent or active TB were more susceptible to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection [11] .

This study found infection with Mycobacterium tuberculosis to be a more common comorbidity for COVID-19 (36%) [11] . They also found Mycobacterium tuberculosis co-All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 11, 2022. ; https://doi.org/10.1101/2022.01.11.22269065 doi: medRxiv preprint 5 infection to be linked to more severe COVID-19 and more rapid progression [12] . Another study conducted in Zambia, revealed that 31.4% post-mortem PTB diagnostic in COVID-19 deaths [13] . In countries where tuberculosis (TB) risk factors for mortality are highly prevalent among young individuals (poverty, overcrowding, diabetes mellitus, smoking, alcohol and substance abuse, HIV co-infection, among others), particularly in the presence of drug resistance and difficult access to diagnosis (delayed diagnosis) [14, 15] , COVID-19 incidence and mortality associated to TB may be hypothesized as significant. However, COVID-19 associated to previous, current or both TB has been lower in high burden TB countries. Both active and previous history of TB may play a deleterious synergism SARS-CoV-2, increasing then the risk of COVID-19 associated mortality, and for patients with PTB may increase the severity of COVID-19 and of death due to chronic lung disease and immunosuppression [8] . This may contribute to higher than expected mortality in high TB burden region such as SSA.

Therefore, there is less information available on COVID-19 associated to TB in point of view incidence and fatality rates in SSA. This systematic review served to provide data synthesis of available evidence on COVID-19/TB incidence and case fatality rates, and case fatality rates found in clinical and post-mortem COVID-19/TB diagnostics in SSA.

The review followed a predesigned protocol registered in PROSPERO (CRD42021233387).

The systematic review met the criteria outlined in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [16] .

A search of the literature was systematically conducted using Pubmed, Medline, Google Scholar, Medrxix and COVID-19 Global literature on coronavirus disease. All searches were All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 11, 2022. ; https://doi.org/10.1101/2022.01.11.22269065 doi: medRxiv preprint 6 limited to articles written in English given that such language restriction does not alter the outcome of systematic reviews and meta-analyses. The search was restricted to studies related to the incidence and case fatality rates of COVID-19 related to TB in SSA since December 2019 to November 2021 including the key words and term as follows: "Covid-19 or 2019-nCoV or coronavirus disease 2019 or Novel coronavirus or SARS-CoV-2 " and "tuberculosis or PTB or TB or Mycobacterium tuberculosis infection" and "mortality rate or death rate or case fatality rate" and "incidence or Incidence proportions or Incidence rate or incidence rate or attack rate" and "Angola or Benin or Botswana or Burkina Faso or Burundi or Cameroon or Cape Verde or "Central African republic" or Chad or Congo or "Democratic Republic of Congo" or DRC or Djibouti or Equatorial guinea or Eritrea or Ethiopia or Gabon or Gambia or Ghana or Guinea or Bissau or Ivory coast or ""Cote d' ivoire" or Kenya or Lesotho or Liberia or Madagascar or Malawi or Mali or Mayotte or Mozambique or Namibia or Niger or Nigeria or Principe or Reunion or Rhodesia or Rwanda or "Sao Tome" or Senegal or "Sierra Leone" or Somalia or "South Africa" or Swaziland or Tanzania or Togo or Uganda or Zambia or Zimbabwe or "Central Africa" or "Sub-Saharan Africa" or "East Africa" or "Southern Africa" or "South Africa", without language restrictions to identify citations from prior to January 2020. The review included observational studies conducted in Sub-Saharan Africa, including the incidence and mortality related to COVID-19 and TB. We included confirmed COVID-19 participants with TB diagnosed previously, currently or in post-mortem.

The methodological quality of the included studies was independently assessed by two of the authors (JLT and GL). Any inconsistencies were resolved by consensus, and if no agreement was reached yet again, the case was resolved by seeking the views of a third author (PB). All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 11, 2022. ; https://doi.org/10.1101/2022.01.11.22269065 doi: medRxiv preprint 7

The Newcastle-Ottawa scale (NOS) [17] was used by two reviewers (JTL and GL) to independently assess study quality. The NOS evaluated the case series, cross-sectional, casecontrol study's selection, comparability, and exposure, as well as the cohort study's selection, comparability, and outcome. The sample with more than 6 stars was considered to be of reasonably high quality, and the sample with nine stars reflects the highest ranking. Any discrepancies in the content of the included studies were resolved with the help of another reviewer (PB).

Three levels of screening were performed. The first and second rounds of screening were based on titles and abstracts only while the third round consisted of a review of full text articles. The first screening was performed by JTL and excluded references that did not contain information on the pathogens of interest or those that were not the study designs of interest (included observational studies only). The second screening was performed independently by JLT and GL with differences solved by consensus. The third level of screening identified those publications related COVID-19 incidence and mortality associated to PTB in SSA and data extraction was performed on those that met the criteria.

Screening and data extraction were performed by JLT and GL independently reviewing each full text article. Conflicts were resolved via discussion to achieve consensus, with any remaining disagreements resolved by a third reviewer. Included studies were observational studies that included COVID-19 incidence and/or mortality related to PTB in SSA.

Data were extracted based on the study year of publication, first author's name, country of study, design, setting, target population, sampling method, sample size, total study period, items related to the quality assessment of the study (the score of each item and the overall study quality score), incidence data and mortality of COVID-19 associated with PTB All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 11, 2022. ; https://doi.org/10.1101/2022.01.11.22269065 doi: medRxiv preprint 8 (including attack rates, death rate, clinical and post-mortem COVID-19/TB diagnostic mortality, cumulative incidence and incidence rate, based on the measured 95% CIs and Pvalues).

The main outcomes were the incidence of COVID-19 associated to current or/and previous PTB and the case fatality rates associated to this proportion. This was calculated as the number of persons developing COVID-19 associated to PTB divided by the total number of COVID-19 cases. Standard errors and confidence intervals for a single proportion were derived. P as the proportion of COVID-19/TB infections (previous and/or current TB) or clinical and post-mortem diagnostics of COVID-19/TB deaths and N was the total number of cases of COVID-19 for the incidence rate and total COVID-19 deaths for the case fatality rate.

The pooled COVID-19 incidence proportion and case fatality rate TB-related were calculated in this meta-analysis. The combination method was based on methodological similarities in the included random effect model studies using Prometa 3 software [18] . Forest plots were plotted for all studies to show the separate and pooled incidence and fatality rates and the corresponding 95% CIs. Both COVID-19/TB incidence proportion and fatality rate were measured in term of the ratios of proportions (RR-Ps). Heterogeneity assessment with the Q-Statistic Test and I 2 -Statistics and their corresponding 95% CIs were used to assess the statistical heterogeneity of incidence and mortality in the included studies. The following references were used as the basis for determining the degree of heterogeneity: (1) Heterogeneity values of 0% -40% will be considered 'maybe not important;' (2) All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 11, 2022. ; https://doi.org/10.1101/2022.01.11.22269065 doi: medRxiv preprint Heterogeneity values of 30% -60% as 'moderate heterogeneity;' (3) Heterogeneity values of 50% -90% as 'substantial heterogeneity;' and (4) Heterogeneity values of 75% -100% as 'significant heterogeneity [19] . The statistical significance level was set at p<0.05 for the Qtest [19] . The subgroup, meta-regression and sensitivity analysis were used to explore potential sources of heterogeneity if the I 2 value was higher than 75%. We also undertook meta-regression to find out the source of heterogeneity.

we explored the publication bias with the funnel plot, Egger's and Begg and Mazumdar's rank correlation tests.

From the 548 references extracted by the literature search (Figure 1) , 64 articles were analysed, among which 33 were excluded with reasons, and 25 studies were selected and included in the meta-analysis and six studies were excluded as they were study protocols. We included a total of 191, 250 COVID-19 infected patients and 11, 452 COVID-19 deaths.

The selected articles reported data from South Africa (n = 9), Nigeria (n = 4), Democratic

Republic of Congo (n = 2), Angola (n=1), Uganda (n = 1), Zambia (n = 5), Ethiopia (n=2) and Kenya (n = 1) (Figure 2 ).

Twenty-five studies were included for quantitative analysis. All the studies analysed clinical characteristics and co-morbidities of COVID-19 patients in SSA. Among them, twenty studies included the incidence proportion of COVID-19 associated to TB [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] , and nine studies included the case fatality rate of COVID-19 associated to TB [13, 20, 30, 33, 38, [40] [41] [42] [43] .

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 11, 2022. ; https://doi.org/10.1101/2022.01.11.22269065 doi: medRxiv preprint 1 0

The minimum age for the study population was 13 years and the maximum was 72 years.

Incidence and mortality of TB associated to COVID-19, stratified by sex were not obvious as all the studies included common co-morbidities associated to COVID-19 without sex stratification. The median study duration was 15 months (range, 4 months to 45 years) and the study period ranged from 2020 to 2021. Eleven studies used retrospective case identification [13, 30-37, 40, 43] , six prospective case identification [20] [21] [22] [23] [24] 39] , and three were Case series [25, 41, 42] , three Cross-sectional studies [26] [27] [28] , one cross-sectional and retrospective cohort study [38] and one case control study [29] (Supplementary material Table 1 ).

The NOS [17] was used to determine the methodological validity of included research for determining the consistency of cohort, case-control, and descriptive studies in meta-analyses.

The three essential components of this strategy are range, comparability, and exposure. For case-control and cohort studies, the NOS employs a star system with ratings ranging from 0 to 9. We considered a study with a higher score than the six of each type of study to be a high-quality study because the criteria for determining whether a study is high or poor quality are unknown. Two studies scored eight, five scored seven, eight scored six, five scored five, and one scored four. Supplementary material Table 2 shows the NOS scores for the studies that were included.

In this review, we defined the incidence proportion as the number of new cases of COVID-19 associated to TB over the total number of people in the population at risk for having COVID-19 during a specified period. The case fatality rate was defined as total number of new deaths 1 1 due to COVID-19 associated to TB divided by the total number of COVID-19 associated to TB. The incidence and case fatality rates were summarized as specific period cases per 100.

In total, 20 studies were identified for incidence proportion of COVID-19 associated to TB in SSA. The pooled RR-P [95% CI] was 2% [1%-3%]. The test for heterogeneity was statistically significant with (I 2 = 93.53 P<0.0001) (Figure 3 ).

We identified nine studies [13, 20, 30, 33, 38, [40] [41] [42] [43] (Figure 4 ).

We built multivariate meta-regression model including cumulative COVID-19 cases, HIV prevalence and TB incidence to explore heterogeneity between studies. People living with HIV (all ages), TB incidence rate and cumulative COVID-19 cases were (7, 800, 000; 360 in thousands; 3, 533, 106) for South Africa, ( (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 11, 2022. ; https://doi.org/10.1101/2022.01.11.22269065 doi: medRxiv preprint 1 2 938) for Angola and ( 1, 400, 000 ; 253 in thousands; 130, 178 ) for Uganda [1, 44, 45] . This model showed that the variability across studies was explained by COVID-19 cumulative cases by countries (P= 0.032), HIV prevalence (P= 0.041) and TB incidence (P= 0.002).

Egger's and Mazumdar's rank correlation test and Begg's funnel plot were used to evaluate publication bias quantitatively and qualitatively respectively. Asymmetry was found in the plot including COVID-19/TB incidence proportion (Figure 5) 

For all the studies including in COVID-19/TB incidence and mortality rates in SSA, sensitivity analysis was performed by sequential omission of every study respectively Prometa 3. For every incidence and mortality rates, the RR-P was not significantly influenced by omitting any single study.

The objective of this review was to help us to estimate the burden of COVID-19 associated with TB in SSA; the meta analysis including twenty studies and 191, 250 COVID-19 infected cases demonstrated that the overall pooled incidence proportion was 2% [1%-3%].

Our COVID-19/TB incidence was higher than the incidence found in a recent meta-analysis forty-three studies which showed the pooled estimate for proportion of active pulmonary tuberculosis was 1.07% [0.81%-1.36%] [46] . This systematic review included more studies All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. had tuberculosis, reported on deaths due to COVID-19 [46] . Our high case fatality rate may be justified by same reasons referred to COVID-19/TB incidence. Interestingly, our review has shown that TB was among the commonest co-morbidity in COVID-19 patients in sub-Saharan Africa. This is consistent with findings in other studies including high TB postmortem diagnostic in sub-Saharan Africa [47, 48] This deleterious synergism of SARS-CoV-2 and Mycobacterium tuberculosis increases the risk of COVID-19-associated morbidity and mortality [8] , and patients with PTB may increase the severity of COVID-19 and death due to chronic lung disease and All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 11, 2022. ; https://doi.org/10.1101/2022.01.11.22269065 doi: medRxiv preprint 1 4 immunosuppression. In fact, advanced PTB is characterized by significant collagen deposition and fibrosis , although tissue remodelling during fibrosis is a healing process, extensive fibrosis with scar formation impairs lung function [51] . A study reported a series of 454 cases of massive fibrosis with evidence of tuberculosis in 40% [52] .

Furthermore, ACE2 has been reported to play a protective role in lung fibrosis [53] . In lung biopsy specimens of patients with lung fibrosis, ACE2 mRNA and enzyme activity decreased significantly [53, 54] . Interestingly, SARS-CoV-2 spike protein decrease the amount of ACE2 expression during viral infection [55] . Decreased ACE2 expression results in increased ANG-II levels and contributes to lung fibrosis and pulmonary failure [53] . In three different acute lung injury models, loss of ACE2 expression precipitated serious acute lung failure, while RhACE2 attenuated ARDS and further decreased Angiotensin II levels in the lungs [56, 57] . In addition to TGFβ and ACE2, other pathways can contribute to SARS-CoV-2 mediated lung fibrosis. MCP-1 is a chemokine that causes lung fibrosis. In addition, there are permanent changes in lung architecture after TB due, in part, to aberrant wound healing processes [58] . Regulation of the TGF-β signalling pathway was also associated with elevated levels of collagen in lung lesions prior to and during TB [58, 59]. The TGF-β activation pathways in both SARS-CoV and PTB contribute to the production of fibrin, collagen and secreted proteases (Matrix metalloproteinases) associated with human cavities involved in the formation of fibrosis and tissue remodelling [51] . As a summary the presence of cavitary lesions, fibrosis and extensive lung pathology was then identified as a major risk factor for poor COVID-19/TB outcomes, which could be explained by reduced drug penetration due to minimal blood supply in fibrotic lungs sites [60] . Lastly, the transient immunosuppression characterized both conditions, a reason for poorer IgG antibody response and a delayed viral clearance in co-infected SARS-CoV-2 patients and the use of corticoid therapy in SARS added even more on immunosuppression [8].

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 11, 2022. ; https://doi.org/10.1101/2022.01.11.22269065 doi: medRxiv preprint 1 5

There are several implications to our findings in screening TB concomitantly to COVID-19 in SSA. Our findings indicate that the risks of COVID-19 associated to previous and/or current TB may be underestimated in SSA, as this co-infection is poorly reported. Although there is a paucity of accurate epidemiological data about COVID-19 associated to previous and/or current TB, the fatality rate is estimated high. Therefore, COVID-19 associated to TB should be taken in a context of proper history taking, accurate diagnostic tools and clear management [8] . Then, clinicians dealing with a possible SARS-CoV-2 patient from high burden TB region, one should never forget TB as a coexisting pathology.

There was a lot of variation between studies that looked at the incidence and case fatality rates. This heterogeneity can be explained by a model that includes cumulative COVID-19 cases, HIV prevalence, and TB incidence, all of which vary significantly across countries.

Meta-regression revealed statistically significant p-values for the relationship between effect size and our model. Furthermore, the RR-P was not significantly influenced by omitting any single study in a sensitivity analysis performed by sequentially omitting every study for every incidence and mortality rate. To assess publication bias quantitatively and qualitatively, Egger's and Mazumdar's rank correlation test and Begg's funnel plot were used. Asymmetry was found in the plot that included the COVID-19/TB incidence proportion (Fig 5) . Because Our systematic review is limited by the quality of the included studies: first, the majority involved retrospective data analyses, which increase the risk of bias associated with the recording of baseline data, the need for imputation, and potential selection bias. Retrospective All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 11, 2022. ; https://doi.org/10.1101/2022.01.11.22269065 doi: medRxiv preprint 1 6 studies did not report how missing data were handled or if imputation was used. High risk of selection bias was noted in retrospective and cross-sectional studies. Finally, the results of the case fatality meta analysis should be interpreted with caution because data pooling the postmortem PTB diagnostic were all extracted in studies conducted in Zambia [13, [41] [42] [43] . This could limit the external validity of the review. Future studies should be properly designed with high quality and systematic methods of TB diagnostic associated with COVID-19. This will play a substantial role in reflecting the true incidence and mortality rates of COVID-19/TB in SSA.

This systematic review of the incidence proportion and case fatality rate of COVID-19 associated to TB in SSA. This analysis showed that the incidence of TB associated with COVID-19 and case fatality rates are higher in SSA. However, COVID-19 associated to TB may be underreported in the studies conducted in SSA due to no specific COVID-19/TB diagnostic tools. This is strengthened by high case fatality rate of COVID-19/TB in postmortem diagnostic. Large-scale cohort studies that adequately clear tool on previous and/or current TB diagnostic tools are required to confirmed COVID-19/TB incidence and case fatality. Reporting Items for Systematic Reviews and Meta-Analyses; PTB: pulmonary tuberculosis; All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 11, 2022. ; https://doi.org/10.1101/2022.01.11.22269065 doi: medRxiv preprint https://www.medrxiv.org/content/10.1101/2020.03.10.20033795v1.full.pdf All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 11, 2022. 

COVID-19) Dashboard. Situation by Region, Country, Territory & Area

Routes for COVID-19 importation in Brazil

Electronic State Parties Self-Assessment Annual Reporting Tool

Seeding COVID-19 across All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity

COVID-19 -Tuberculosis interactions: When dark forces collide

Covid-19 deaths in Africa: prospective systematic postmortem surveillance study

Worldwide Effects of Coronavirus Disease Pandemic on Tuberculosis Services

Pathology of TB/COVID-19 Co-Infection: The phantom menace

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta

Cochrane handbook for systematic reviews of interventions

Risk Factors for Coronavirus Disease 2019 (COVID-19) Death in a Population Cohort Study from the Western Cape Province, South Africa

Clinical Characteristics and Outcomes of Patients Hospitalized for COVID-19 in Africa: Early Insights from the Democratic Republic of the Congo

Clinical Experience With Severe Acute Respiratory Syndrome Coronavirus 2-Related Illness in Children: Hospital Experience in Cape Town, South Africa

Characteristics and outcomes of admitted patients infected with SARS-CoV-2 in Uganda

Effect of co-infection with parasites on severity of COVID-19. medRxiv

Clinical characteristics of the first 100 COVID-19 patients admitted to a tertiary hospital in

Clinical and Demographic Characteristics of COVID-19 patients in Lagos, Nigeria: A Descriptive Study

High HIV prevalence in an early cohort of hospital admissions with COVID-19 in Cape Town

Morbidity and mortality outcomes of COVID-19 patients with and without hypertension in Lagos, Nigeria: a retrospective cohort study

Clinical features and risk factors associated with morbidity and mortality among patients with COVID-19 in northern Ethiopia

Predictors of mortality in COVID-19 patients at Kinshasa University Hospital

Epidemiology of COVID-19 and Predictors of Outcome in Nigeria: A Single-Center Study

Evaluation of patient characteristics, management and outcomes for COVID-19 at district hospitals in the Western Cape, South Africa: descriptive observational study

COVID-19 Severity and COVID-19-Associated Deaths Among Hospitalized Patients with HIV Infection -Zambia

COVID deaths in South Africa: 99 days since South Africa's first death

Histopathological Evaluation of Deceased Persons in Lusaka, Zambia With or Without Coronavirus Disease 2019 (COVID-19) Infection: Results Obtained From Minimally Invasive Tissue Sampling

COVID-19 and Sudden Unexpected Community Deaths in Lusaka, Zambia, Africa -A Medico-Legal Whole-Body Autopsy Case Series

Post-mortem examination of Hospital Inpatient

Deaths in Lusaka, Zambia -A Descriptive Whole-body Autopsy Series

Active pulmonary tuberculosis and coronavirus disease 2019: A systematic review and metaanalysis

Burden of tuberculosis at post mortem in inpatients at a tertiary referral centre in sub-Saharan Africa: a prospective descriptive autopsy study

Prevalence of tuberculosis in postmortem studies of HIV-infected adults and children in resource-limited settings: a systematic review and meta-analysis

Pathology of post primary tuberculosis of the lung: an illustrated critical review

Lesion-Specific Immune Response in Granulomas of Patients with Pulmonary Tuberculosis: A Pilot Study

Effects of host-directed therapies on the pathology of tuberculosis

The prevalence of tuberculosis at necropsy in progressive massive fibrosis of coalworkers

Molecular Biology of the SARS-Coronavirus

Angiotensin converting enzyme-2 is protective but downregulated in human and experimental lung fibrosis

A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury

Angiotensin-converting enzyme 2 protects from severe acute lung failure

The Pathophysiology of COVID-19 and SARS-CoV-2 Infection: Disequilibrium between the classic renin

Competing interests: None of the authors in this study have any conflict of interest regarding the publication of the paper.All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted January 11, 2022. ; https://doi.org/10.1101/2022.01.11.22269065 doi: medRxiv preprint 2 0 All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted January 11, 2022. ; https://doi.org/10.1101/2022.01.11.22269065 doi: medRxiv preprint 2 1 All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. https://www.medrxiv.org/content/10.1101/2020.11.09.20228106v1All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted January 11, 2022. ; https://doi.org/10.1101/2022.01.11.22269065 doi: medRxiv preprint 2 3All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted January 11, 2022. ; https://doi.org/10.1101/2022.01.11.22269065 doi: medRxiv preprint 2 4All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted January 11, 2022. ; https://doi.org/10.1101/2022.01.11.22269065 doi: medRxiv preprint 2 5All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted January 11, 2022. ; https://doi.org/10.1101/2022.01.11.22269065 doi: medRxiv preprint 2 6All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted January 11, 2022. ; https://doi.org/10.1101/2022.01.11.22269065 doi: medRxiv preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted January 11, 2022. ; https://doi.org/10.1101/2022.01.11.22269065 doi: medRxiv preprint 2 8All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted January 11, 2022. ; https://doi.org/10.1101/2022.01.11.22269065 doi: medRxiv preprint All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted January 11, 2022. ; https://doi.org/10.1101/2022.01.11.22269065 doi: medRxiv preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted January 11, 2022. ; https://doi.org/10.1101/2022.01.11.22269065 doi: medRxiv preprint Figure 3 : pooled incidence proportion of COVID-19 associated to TB in sub-Saharan Africa All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted January 11, 2022. ; https://doi.org/10.1101/2022.01.11.22269065 doi: medRxiv preprint Figure 4 : pooled case fatality rate of COVID-19 associated to TB All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted January 11, 2022. ; https://doi.org/10.1101/2022.01.11.22269065 doi: medRxiv preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted January 11, 2022. ; https://doi.org/10.1101/2022.01.11.22269065 doi: medRxiv preprint